

STHFT Board of Directors Research Update



Dr Peter Sneddon
Clinical Research Office
Director

Aim of the STHFT Research Strategy

To increase the **quantity, quality and impact of clinical research** so that it is viewed as essential and valued activity by all members of the organisation and the wider Sheffield community

Implementation of the Research Strategy

- **Create a Clinical Research Academy** with the University of Sheffield
 - School of Health and Related Research (ScHARR)
 - Award 2 PAs for clinical research time following open competition
 - Call for applications was issued in February 2015 as planned
 - First Fellows will be selected by an expert review panel in June/July 2015

Implementation of the Research Strategy

- Academic Directorates will act as role models in:
 - Meeting NIHR national metrics
 - Increasing research capacity and output
 - Generating NIHR grant and other income
- Formal reviews of Directorate's research performance started in January 2015
- 1 PA to each Academic Directorate's Research Director
- Other Directorates, 1hr or 2hr per week PA equivalents to Research Lead
- **Implementation of the Research Strategy is supported by a new Performance and Operating Framework**

Performance and Operating Framework

- Develop effective performance management processes for delivery of the Research Strategy
- Monitor the research performance of each Directorate against a range of metrics
- Academic Directorate status based on a transparent, annual review process
- **Develop a system of performance-based funding allocations in STHFT**

Review of Academic Directorate status

- Each Directorate provided;
 - Directorate Research Strategy
 - Directorate Annual Plan
 - SMART objectives and targets
- A quarterly update and annual report on the delivery of metrics against target
- An annual impact statement on benefits to patients and the public
- An annual commentary from the Directorate research lead reviewing their performance

Directorate Performance Summary

| SMART Objective | Target | 2014/15 performance | | | | | 2015/16 performance | | | | | 2016/17 performance | | | | | |
|--|--|--|----|----|----|--------------|---------------------|----|----|----|--------------|---------------------|----|----|----|--------------|--|
| | | Q1 | Q2 | Q3 | Q4 | Year to date | Q1 | Q2 | Q3 | Q4 | Year to date | Q1 | Q2 | Q3 | Q4 | Year to date | |
| 1 | Number of research active staff | 32 | - | | | | | | | | | | | | | | |
| 2 | Number of research publications | 48 | - | | | | | | | | | | | | | | |
| 3 | Number of grant applications submitted | 4 | | | | | | | | | | | | | | | |
| 4 | Number of grants awarded | 1 | | | | | | | | | | | | | | | |
| 5 | Total value of successful grant applications | £250,000 | | | | | | | | | | | | | | | |
| 6 | Amount of income to STH | £25,000 | | | | | | | | | | | | | | | |
| 7 | Number of active portfolio studies | 38 | - | | | | | | | | | | | | | | |
| 8 | Total number of patient accruals to studies | 125 | | | | | | | | | | | | | | | |
| 9 | 70 day benchmark (%) | 80 | | | | | | | | | | | | | | | |
| 10 | Recruitment to time and target (%) | 75 | | | | | | | | | | | | | | | |
| 11 | Directorate specific KPIs | None | | | | | | | | | | | | | | | |
| 12 | Patient and public benefits | <p>The Directorate has a Research Executive that carefully evaluates the clinical relevance of all research proposals within the Directorate with the aim of encouraging research that has high relevance to patient benefit. In addition, our patient and public lay advisory panel (established in 2013) also evaluates our research proposals. Researchers from our Directorate have had a leading role in the DAFNE project, which has benefited patients worldwide by enabling them to self manage their type 1 diabetes more effectively. Our endocrine researchers are developing new therapies which will directly benefit the quality of life and symptoms of patients with adrenal insufficiency. Resulting from the late effects of cancer therapy research, specialist clinics were found to be effective and have now been implemented.</p> | | | | | | | | | | | | | | | |
| Directorate commentary on performance: | | <p>Our expertise in interventional studies, which while attracting income do not result in participation of large numbers. We will address this by exploring, particularly within the York/Humber CRN the opportunity to participate in large scale observational studies. These include ADDRESS2 and Trial Net but we are aware of other studies (DARE) and that we are exploring the possibility of our participation.</p> | | | | | | | | | | | | | | | |

Review of Directorates' performance

- 8 current Academic Directorates were reviewed in January 2015
 - Cardiology & Cardiothoracic Surgery, Communicable Diseases, Diabetes and Endocrinology, Neurosciences, Oral and Dental Respiratory Medicine, Specialised Cancer, Specialised Medicine
- Directorates applying for Academic Directorate Status reviewed in March 2015
 - A&E, OG&N, Professional Services, Renal, Urology (MIMP tbc)
- Review panel will make recommendations to the STH Research Committee in April 2015

STHFT Board of Directors Research Update



NIHR Clinical Research Network Yorkshire and Humber

Host perspective on NIHR YH CRN

- All key objectives have been delivered on schedule
- STHFT provided HR support and appointed key staff
- We have a leadership team distributed across the region
- We provide financial management for the Network
- Funding allocation for 2015/16 is £28.1 million
- STHFT to agree the YH CRN Annual Plan and Financial plan for 2015/16
- **Main challenge ahead - deliver 2015/16 Annual Plan HLOs, particularly the efficient recruitment of patients onto clinical trials**

Key messages from the national metrics

- STHFT is currently recruiting 97% of its agreed NIHR target number of patients to trials (7,900)
- YH CRN is recruiting the third largest number of patients of the 15 CRNs in England (9.9%)
- YH CRN is currently achieving only 80% of its NIHR recruitment target (67,000)
- YH CRN performance is below the national average of CRNs in England
- **YH CRN must address the variation in the performance of the 22 Partner Organisations**

STHFT Board of Directors Research Update



Dr Peter Sneddon
Clinical Research Office
Director